Pan-Canadian ODR recommendation supports use of Tagrisso for NSCLC subset

The pan-Canadian Oncology Drug Review (pCODR) has issued a positive clinical recommendation of the reimbursement of Tagrisso (osimertinib), a novel, targeted treatment for a subset of non-small cell lung cancer (NSCLC) patients.

Tagrisso, from Anglo-Swedish pharma major AstraZeneca (LSE: AZN), is the first and only oral, targeted therapy shown to shrink tumor size and slow disease progression in patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive NSCLC who have progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy, the company stated.